Pipeline
Passion for Discovery
pipeline
Agios has leveraged its core capabilities in cellular metabolism and precision medicine to build a product engine that is focused in the therapeutic areas of cancer and rare genetic diseases.
CANDIDATE
Drug Discovery
Early Stage Clinical Development
Late Stage Clinical Development
Regulatory Submission
APPROVED
R/R AML
Phase 1 Dose-Escalation and Expansion
EU
U.S.
Frontline AML Monotherapy
Phase 1 Dose-Escalation and Expansion
U.S.
IC-Eligible Frontline AML
Phase 1b 7+3 Combo
Phase 3 HOVON 7+3 Combo
IC-Ineligible Frontline AML
Phase 1/2 Azacitidine Combo
Phase 3 AGILE Azacitidine Combo
Cholangio
Phase 1 Dose-Escalation and Expansion
Phase 3 ClarlDHy
R/R MDS
Phase 1 Expansion
R/R AML
Phase 3 IDHENTIFY
U.S.
IC-Eligible Frontline AML
Phase 1b 7+3 Combo
Phase 3 HOVON 7+3 Combo
IC-Ineligible Frontline AML
Phase 1/2 Azacitidine Combo
- Celgene has worldwide development and commercialization rights.Agios has U.S. co–promotion and royalty rights.
PK Deficiency – Not Regularly Transfused
Phase 2 DRIVE PK
Phase 3 ACTIVATE
PK Deficiency – Regularly Transfused
Phase 3 ACTIVATE-T
Thalassemia
Phase 2 Study
MTAP-Deleted NSCLC and Pancreatic Cancer
Phase 1 Dose-Escalation and Expansion
Healthy Volunteers
Phase 1 Planned
IC = Intensive Chemotherapy
The safety and efficacy of the agents and uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.